Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.207
Neutral
RSI(14)
43.424
Neutral
STOCH(KDJ)(9,3,3)
55.554
Sell
ATR(14)
0.618
High Vlolatility
CCI(14)
-92.474
Neutral
Williams %R
57.321
Sell
TRIX(12,20)
-0.148
Sell
StochRSI(14)
0.000
Sell
Baxter International Inc
BAX23.810USD
-0.180-0.75%
Close 09/15, 16:00（ET）Quotes delayed by 15 min
12.23BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Currency: USD Updated：2025-09-12Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
18
analysts
Hold
Current Rating
29.391
Target Price
+22.52%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of its sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. It provides a portfolio of diagnostic, critical care, nutrition, hospital and surgical products.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD 649.00M.%!(EXTRA int=2)
Undervalued
The company’s latest PE is -78.78, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 507.74M shares, decreasing 4.36% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 61.95M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.67.
Financial Health
Currency: USD Updated：2025-09-12The company's current financial score is 7.33, which is higher than the Healthcare Equipment & Supplies industry's average of 7.15. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 2.62B, representing a year-over-year increase of 5.42%, while its net profit experienced a year-over-year increase of 240.54%.
Score
Financials
8.39
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data
Quality of Earnings
5.83
Operational Efficiency
7.67
Growth Potential
8.59
Shareholder Returns
6.15
Company Valuation
Currency: USD Updated：2025-09-12The company’s current valuation score is 1.20, which is lower than the Healthcare Equipment & Supplies industry's average of 2.15. Its current P/E ratio is -80.55, which is -108.89% below the recent high of 7.16 and 86.59% above the recent low of -10.80.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 74/207
No Data
Earnings Forecast
Currency: USD Updated：2025-09-12The company’s current earnings forecast score is 6.22, which is lower than the Healthcare Equipment & Supplies industry's average of 7.66. The average price target for Baxter International Inc is 25.50, with a high of 52.12 and a low of 19.00.
Score
Support & Resistance
No Data
Analyst Rating
Based on
18
analysts
Hold
Current Rating
29.391
Target Price
+22.52%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
118
Total
7
Median
8
Average
Company name
Ratings
Analysts
Baxter International Inc
BAX
18
Medtronic PLC
MDT
35
Stryker Corp
SYK
33
Abbott Laboratories
ABT
31
Zimmer Biomet Holdings Inc
ZBH
30
Dexcom Inc
DXCM
29
1
2
3
...
24
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
No Data
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated：2025-09-12The company’s current price momentum score is 8.98, which is higher than the Healthcare Equipment & Supplies industry's average of 7.47. Sideways: Currently, the stock price is trading between the resistance level at 25.84 and the support level at 22.28, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
24.142
Sell
MA10
24.051
Sell
MA20
24.190
Sell
MA50
25.578
Sell
MA100
28.111
Sell
MA200
29.936
Sell
Institutional Confidence
Currency: USD Updated：2025-09-12The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. The latest institutional shareholding proportion is 98.85%, representing a quarter-over-quarter decrease of 0.16%. The largest institutional shareholder is The Vanguard, holding a total of 61.95M shares, representing 12.06% of shares outstanding, with 1.65% increase in holdings.
Score
Institutional Shareholding
No Data
Shareholder Activity
Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
State Street Global Advisors (US)
BlackRock Financial Management, Inc.
Geode Capital Management, L.L.C.
BlackRock Investment Management, LLC
1
2
Risk Assessment
Currency: USD Updated：2025-09-12The company's beta value is 0.60. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.59
VaR
+2.74%
240-Day Maximum Drawdown
+44.08%
240-Day Volatility
+37.86%
Return
Best Daily Return
60 days
+4.62%
120 days
+9.94%
5 years
+9.94%
Worst Daily Return
60 days
-22.42%
120 days
-22.42%
5 years
-22.42%
Sharpe Ratio
60 days
-1.58
120 days
-1.13
5 years
-0.57
Risk Assessment
Maximum Drawdown
240 days
+44.08%
3 years
+61.51%
5 years
+75.67%
Return-to-Drawdown Ratio
240 days
-0.86
3 years
-0.30
5 years
-0.18
Skewness
240 days
-2.60
3 years
-2.18
5 years
-2.08
Volatility
Realised Volatility
240 days
+37.86%
5 years
+29.41%
Standardised True Range
240 days
+3.76%
5 years
+5.05%
Downside Risk-Adjusted Return
120 days
-113.11%
240 days
-113.11%
Maximum Daily Upside Volatility
60 days
+38.46%
Maximum Daily Downside Volatility
60 days
+49.47%
Liquidity
Average Turnover Rate
60 days
+1.31%
120 days
+1.08%
5 years
--
Turnover Deviation
20 days
+67.30%
60 days
+41.88%
120 days
+17.36%
Peer Comparison
Healthcare Equipment & Supplies
Baxter International Inc
BAX
5.95 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Insulet Corp
PODD
7.87 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cencora Inc
COR
7.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Stevanato Group SpA
STVN
7.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
STERIS plc
STE
7.38 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Abbott Laboratories
ABT
7.33 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
